Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast CancerRita Nanda, Laura J. Esserman, Minetta C. Liu et al.|JAMA Oncology|2020Cited by 707
Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIALNola M. Hylton, Mitchell D. Schnall, Jeffrey D. Blume et al.|Radiology|2012Cited by 487
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Laura J. Esserman, Christina Yau et al.|Cancer Cell|2021Cited by 330
Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival—Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIALNola M. Hylton, Sandra M. Polin, Gillian M. Newstead et al.|Radiology|2015Cited by 276
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 TrialA. Jo Chien, Laura J. Esserman, Debasish Tripathy et al.|Journal of Clinical Oncology|2020Cited by 113